Luciani L, Oriana S, Spatti G, Secreto G, Recchione C, Grignoglio E, Andreola S, Coradini D, Ronchi E, Di Fronzo G
Tumori. 1984 Apr 30;70(2):189-92. doi: 10.1177/030089168407000214.
Twenty-four patients with endometrial carcinoma received tamoxifen (Nolvadex) for 7 days. Before and after administration, circulating hormones (estradiol, testosterone, progesterone, gonadotropins FSH and LH) were evaluated. Estrogen (ER) and progesterone receptors (PgR) in neoplastic tissue were also assayed. Our results show a net increase in PgR content and a significant decrease in gonadotropin levels after the treatment. The authors suggest that clinical trials be conducted using tamoxifen and progestins for adjuvant therapy after surgery of endometrial carcinoma and for the therapeutic approach of advanced carcinoma.
